

Devyser signs first commercial reagent rental agreement under Illumina collaboration in Italy

Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial agreement under its Systems Integrator collaboration with Illumina. The agreement, signed with an Italian laboratory, marks an important step in expanding access to next-generation sequencing (NGS) by combining Illumina instrumentation with Devyser's assay portfolio.

The agreement includes the placement of an Illumina MiSeq™ i100 System under a reagent rental model. The customer will also utilize Devyser's Amplicon Suite software to support data analysis and reporting.

"Laboratories are increasingly looking for easy-to-implement NGS solutions," says Jan Wahlström, CEO of Devyser. "This agreement represents an important win for Devyser as the first commercial implementation under our reagent rental collaboration with Illumina. By combining Illumina's sequencing technology with Devyser's comprehensive assay portfolio and intuitive software, we can make advanced genetic analysis more accessible for laboratories looking to adopt or expand NGS without significant upfront capital investment."

The Italian laboratory will implement a range of Devyser's assays through the reagent rental offering, demonstrating the breadth of the company's portfolio. By replacing upfront capital investment with a predictable reagent purchasing commitment, the model lowers the barrier for laboratories to adopt advanced molecular analysis and modernize their workflows.

Italy continues to be one of Devyser's most important strategic markets, and this reagent rental agreement further strengthens the company's commercial presence while demonstrating the value of its collaboration with Illumina. The multi-year reagent commitment also underpins recurring, higher-visibility revenue for Devyser, and the agreement is expected to serve as a reference for additional reagent rental opportunities across Europe.

For more information, please contact:

Jan Wahlström, CEO

Email: ir@devyser.com

Telephone: +46 8 562 158 50



PRESS RELEASE
06 August 2026 08:00:00 CEST

About Devyser

Devyser is redefining how laboratories approach genetic testing. As your true one-stop shop, we offer streamlined solutions for a wide range of conditions, helping labs overcome complexity, reduce turnaround times, and maximize efficiency.

Our technologies simplify workflows, minimize hands-on time, and deliver fast, accurate results. Every test is designed to empower labs to do more with less, freeing up resources while supporting better patient outcomes.

We specialize in diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories - two critical areas where accuracy and speed matter. With customers in 65+ countries, we also operate our own CLIA-certified laboratory, Devyser Genomic Laboratories, in Atlanta and maintain sales offices across Europe and the US.

Devyser is committed to regulatory excellence under IVDR, ensuring the highest quality standards across our growing product portfolio.

Founded in 2004 and headquartered in Stockholm, Devyser is listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). Redeye Nordic Growth AB is the company's Certified Adviser.

Discover how we're shaping the future of lab diagnostics at www.devyser.com.